Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0191120180330010006
Journal of Korean Medical Science
2018 Volume.33 No. 1 p.6 ~ p.6
Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Kim Soon-Sun

Cho Hyo-Jung
Nam Ji-Sun
Kim Hyun-Ji
Kang Dae-Ryong
Won Je-Hwan
Kim Jin-Oo
Kim Jai-Keun
Lee Jei-Hee
Kim Bo-Hyun
Lee Mi-Young
Cho Sung-Won
Cheong Jae-Youn
Abstract
Background: We investigated an association between the levels of plasma microRNA (miRNA)-21, -26a, and -29a-3p and treatment outcomes following transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

Methods: A total of 198 patients with TACE-treated HCC were followed up for TACE refractoriness and liver transplantation (LT)-free survival. Pretreatment plasma miRNA-21, -26a, and -29a-3p levels were measured using quantitative real-time polymerase chain reaction.

Results: During the mean follow-up of 22.3 (range, 0.7?79) months, 118 (59.6%) patients exhibited TACE refractoriness. Multivariate analyses showed that expression of a specific combination of miRNAs (miRNA-21 ¡Ã 2.5, miRNA-26a ¡Ã 1.5, and miRNA-29a-3p < 0.4) was associated with early TACE refractoriness (within 1 year; hazard ratio [HR], 2.32; 95% confidence interval [CI], 1.08?4.99; P = 0.031) together with tumor size (HR, 4.62; 95% CI, 1.50?14.21; P = 0.008), and macrovascular invasion (HR, 3.80; 95% CI, 1.19?12.20; P = 0.025). However, miRNA-21, -26a, and -29a-3p levels were not significantly associated with overall TACE refractoriness or LT-free survival. Additionally, large tumor size and macrovascular invasion were common predictive factor of overall TACE refractoriness and survival.

Conclusion: Combination of plasma miRNA-21, -26a, and -29a-3p expression could predict early TACE refractoriness in patients with TACE-treated HCC.
KEYWORD
Chemoembolization, Therapeutic, Hepatitis B, Chronic, Carcinoma, Hepatocellular, MicroRNAs
FullTexts / Linksout information
 
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø